FR1840M - - Google Patents
Download PDFInfo
- Publication number
- FR1840M FR1840M FR893528A FR893528A FR1840M FR 1840 M FR1840 M FR 1840M FR 893528 A FR893528 A FR 893528A FR 893528 A FR893528 A FR 893528A FR 1840 M FR1840 M FR 1840M
- Authority
- FR
- France
- Prior art keywords
- product
- administration
- amide
- doses
- animals
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 241001465754 Metazoa Species 0.000 claims description 7
- 150000001408 amides Chemical class 0.000 claims description 7
- SODPIMGUZLOIPE-UHFFFAOYSA-N (4-chlorophenoxy)acetic acid Chemical compound OC(=O)COC1=CC=C(Cl)C=C1 SODPIMGUZLOIPE-UHFFFAOYSA-N 0.000 claims description 5
- 208000020401 Depressive disease Diseases 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 241000699670 Mus sp. Species 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 206010058667 Oral toxicity Diseases 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 230000001430 anti-depressive effect Effects 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 claims description 2
- CDZOGLJOFWFVOZ-UHFFFAOYSA-N n-propylaniline Chemical compound CCCNC1=CC=CC=C1 CDZOGLJOFWFVOZ-UHFFFAOYSA-N 0.000 claims description 2
- 231100000418 oral toxicity Toxicity 0.000 claims description 2
- 230000003236 psychic effect Effects 0.000 claims description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 4
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 206010010904 Convulsion Diseases 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 229940126601 medicinal product Drugs 0.000 claims 3
- 201000003631 narcolepsy Diseases 0.000 claims 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims 2
- 208000001953 Hypotension Diseases 0.000 claims 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 2
- 206010062519 Poor quality sleep Diseases 0.000 claims 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 2
- 230000036528 appetite Effects 0.000 claims 2
- 235000019789 appetite Nutrition 0.000 claims 2
- 230000004872 arterial blood pressure Effects 0.000 claims 2
- 230000036772 blood pressure Effects 0.000 claims 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 2
- 230000036543 hypotension Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000037023 motor activity Effects 0.000 claims 2
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 241000700159 Rattus Species 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000001133 acceleration Effects 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 238000013019 agitation Methods 0.000 claims 1
- 229960000212 aminophenazone Drugs 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 210000003403 autonomic nervous system Anatomy 0.000 claims 1
- 230000008602 contraction Effects 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- UZBQIPPOMKBLAS-UHFFFAOYSA-N diethylazanide Chemical compound CC[N-]CC UZBQIPPOMKBLAS-UHFFFAOYSA-N 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000005284 excitation Effects 0.000 claims 1
- 230000005021 gait Effects 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007928 intraperitoneal injection Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims 1
- 229910052753 mercury Inorganic materials 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 208000022821 personality disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- -1 phenyl-2 methyl-1 ethyl Chemical group 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 230000007425 progressive decline Effects 0.000 claims 1
- 239000003368 psychostimulant agent Substances 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 1
- 230000036387 respiratory rate Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- VRBVHQUSAOKVDH-UHFFFAOYSA-N 2-(4-chlorophenoxy)acetyl chloride Chemical compound ClC(=O)COC1=CC=C(Cl)C=C1 VRBVHQUSAOKVDH-UHFFFAOYSA-N 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- KWTSXDURSIMDCE-UHFFFAOYSA-N 1-phenylpropan-2-amine Chemical compound CC(N)CC1=CC=CC=C1 KWTSXDURSIMDCE-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 238000010907 mechanical stirring Methods 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OPKXKBSMMAECPR-UHFFFAOYSA-N 2-(4-chlorophenoxy)-n-methyl-n-(1-phenylpropan-2-yl)acetamide Chemical compound C=1C=C(Cl)C=CC=1OCC(=O)N(C)C(C)CC1=CC=CC=C1 OPKXKBSMMAECPR-UHFFFAOYSA-N 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- DBJNWDVLSZLQOL-UHFFFAOYSA-N n-methyl-n-propan-2-ylaniline Chemical compound CC(C)N(C)C1=CC=CC=C1 DBJNWDVLSZLQOL-UHFFFAOYSA-N 0.000 description 1
- FRCFWPVMFJMNDP-UHFFFAOYSA-N n-propan-2-ylaniline Chemical compound CC(C)NC1=CC=CC=C1 FRCFWPVMFJMNDP-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA745650A CA745650A (en) | 1962-04-06 | Amides | |
| FR893528A FR1840M (en)) | 1962-04-06 | 1962-04-06 | |
| CH411763A CH412847A (fr) | 1962-04-06 | 1963-04-01 | Procédé de préparation d'un amide stimulant l'activité psychique et anti-dépressive |
| BE630560A BE630560A (en)) | 1962-04-06 | 1963-04-03 | |
| GB13729/63A GB1031904A (en) | 1962-04-06 | 1963-04-05 | Substituted phenoxy-acetic acid amides |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR893528A FR1840M (en)) | 1962-04-06 | 1962-04-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FR1840M true FR1840M (en)) | 1963-07-05 |
Family
ID=8776225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR893528A Expired FR1840M (en)) | 1962-04-06 | 1962-04-06 |
Country Status (5)
| Country | Link |
|---|---|
| BE (1) | BE630560A (en)) |
| CA (1) | CA745650A (en)) |
| CH (1) | CH412847A (en)) |
| FR (1) | FR1840M (en)) |
| GB (1) | GB1031904A (en)) |
-
0
- CA CA745650A patent/CA745650A/en not_active Expired
-
1962
- 1962-04-06 FR FR893528A patent/FR1840M/fr not_active Expired
-
1963
- 1963-04-01 CH CH411763A patent/CH412847A/fr unknown
- 1963-04-03 BE BE630560A patent/BE630560A/fr unknown
- 1963-04-05 GB GB13729/63A patent/GB1031904A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| CA745650A (en) | 1966-11-01 |
| GB1031904A (en) | 1966-06-02 |
| CH412847A (fr) | 1966-05-15 |
| BE630560A (en)) | 1963-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0506539B1 (fr) | Amides alkyl hétérocycliques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
| EP0068999A1 (fr) | Dérivés d'aryl-1 aminométhyl-2 cyclopropanes carboxamides (Z), leur préparation et leur application en tant que médicaments utiles dans le traitement des troubles du système nerveux central | |
| CH637927A5 (fr) | Derives de 4-amino-5-alkylsulfonyl ortho-anisamides et leurs procedes de preparation. | |
| FR2680507A1 (fr) | Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. | |
| EP0562956A1 (fr) | Nouvelles naphtylalkylamines leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
| EP0046707B1 (fr) | Dérivés de l'acide amino-4 butyrique et les médicaments, actifs notamment sur le système nerveux central, en contenant | |
| EP0779284B1 (fr) | Nouveaux dérivés de 2-naphthamides et leurs applications thérapeutiques comme agonistes des récepteurs D3 | |
| EP0000299B1 (fr) | Nouveaux dérivés de benzoyl-2-chloro-4-glycinanilides substitués, leur procédé de préparation et leur application en tant que médicaments. | |
| EP0068998B1 (fr) | Aryl-1 aminométhyl-2 cyclopropanes carboxylates (Z), leur préparation et leur application en tant que médicaments utiles dans le traitement d'algies diverses | |
| EP0366511A1 (fr) | Nouveaux dérivés benzoxazolinoniques, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent | |
| FR1840M (en)) | ||
| EP0165155A1 (fr) | Nouveaux N-acyl dérivés d'amino acides et leurs esters, leur procédé de préparation et médicaments les contenant | |
| EP0077720A1 (fr) | Dérivés de biphényl alcoyl carboxylates, leur procédé de préparation et leur utilisation comme médicaments | |
| CA2576393C (fr) | Nouveaux derives du 3,5-seco-4-nor-cholestane et leurs utilisations | |
| FR2610932A1 (fr) | Nouvel acide piperazinecarboxylique, sa preparation et son utilisation comme medicament | |
| CA1091233A (fr) | Procede de preparation de nouveaux indoles substitues | |
| CH630608A5 (fr) | Procedes de preparation de derives actifs de l'uree. | |
| EP0035619B1 (fr) | Dérivés d'amino-3 (1H,3H) quinazolinedione-2,4 | |
| EP0359627A1 (fr) | Nouveaux derives de dihydro-2,3 arylalcoylaminoalcoyl-3 4H-benzoxazine-1,3 ones-4 leur préparation et leur application en tant que médicaments utiles en thérapeutique | |
| EP0010030B1 (fr) | Nouveaux dérivés d'ortho chloro benzoyl-2 chloro-4 glycylanilide, leur préparation et leur application en tant que médicaments | |
| EP0347305B1 (fr) | [(Aryl-4-pipérazinyl-1)-2 éthoxy]-3 p-cymène, les dérivés ortho, méta, para monosubstitués ou disubstitués sur le noyau phényle dudit produit, le procédé de préparation desdits dérivés, et les médicaments contenant lesdits composés comme principe actif | |
| EP0082040B1 (fr) | Dérivés de diaza-3,7a cyclohepta(j,k)fluorènes, leur préparation et leur application en thérapeutique | |
| FR2505824A1 (fr) | Derives d'isoprenylamine et leur application a des compositions pharmaceutiques | |
| CH658786A5 (fr) | Medicaments qui contiennent d'alpha-(n-pyrrolyl)-acides ou de leurs sels ou esters. | |
| EP0035945A2 (fr) | Nouvelles guanidines acylées, urées et urées substituées, leur procédé de fabrication et leur application en tant que médicaments |